What is the Elacestrant?

Elacestrant is , while it's Molecular Formula is C30H38N2O2. Used in Oncology: Elacestrant is used as a potential treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It targets the estrogen receptor, inducing its degradation, which leads to a decrease in estrogen receptor expression and signaling, ultimately inhibiting cancer cell growth and proliferation. Used in Clinical Trials: Elacestrant is currently being evaluated in clinical trials to further assess its safety and effectiveness as a potential treatment for breast cancer. These trials aim to determine its potential for improved efficacy and reduced side effects compared to other hormone therapy options for breast cancer.

What is the CAS number for Elacestrant?

The CAS number of Elacestrant is 722533-56-4.

What is Elacestrant (722533-56-4) used for?

Elacestrant is a selective estrogen receptor degrader (SERD) that is being developed as a potential treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It works by targeting the estrogen receptor and inducing its degradation, leading to a decrease in estrogen receptor expression and signaling. This ultimately results in the inhibition of cancer cell growth and proliferation. Elacestrant has shown promising results in preclinical and early clinical studies, with potential for improved efficacy and reduced side effects compared to other hormone therapy options for breast cancer.

What is the Elacestrant?

Elacestrant is , while it's Molecular Formula is C30H38N2O2. Used in Oncology: Elacestrant is used as a potential treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It targets the estrogen receptor, inducing its degradation, which leads to a decrease in estrogen receptor expression and signaling, ultimately inhibiting cancer cell growth and proliferation. Used in Clinical Trials: Elacestrant is currently being evaluated in clinical trials to further assess its safety and effectiveness as a potential treatment for breast cancer. These trials aim to determine its potential for improved efficacy and reduced side effects compared to other hormone therapy options for breast cancer.

What is the CAS number for Elacestrant?

The CAS number of Elacestrant is 722533-56-4.

What is Elacestrant (722533-56-4) used for?

Elacestrant is a selective estrogen receptor degrader (SERD) that is being developed as a potential treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It works by targeting the estrogen receptor and inducing its degradation, leading to a decrease in estrogen receptor expression and signaling. This ultimately results in the inhibition of cancer cell growth and proliferation. Elacestrant has shown promising results in preclinical and early clinical studies, with potential for improved efficacy and reduced side effects compared to other hormone therapy options for breast cancer.